info@glytecsystems.com
About Glytec
eGlycemic Management System
Chronic Care Management
Sliding Scale to Basal Bolus Transition
Hospital Pharmacy Resources
Announcement Type Research Study Client Partner Patent Product FDA Clearance Event Case Study Employee Certification
Topic A1C Reduction Academic Medical Center Basal Bolus Adoption Blood Glucose Monitoring CABG Surgery Patients CMS Hypoglycemia Measure Connected Diabetes Technologies Continuous Glucose Monitoring Cost of Care Reduction Critical Care Patients Diabetic Ketoacidosis (DKA) Resolution eGlycemic Management System® Emergency Department EMR Integration Geriatric Patients Glucommander™ H2H® (Hospital to Home) Glucommander™ Outpatient Glucose Meter Health System Heart Failure Patients Hyperglycemia Reduction Hypoglycemia Reduction Inpatient Glycemic Management International IV Insulin Kidney Disease Length of Stay Reduction Mortality Rate Reduction Outcomes Improvement Outpatient Glycemic Management Psychiatric Patients Readmissions Reduction Steroid Use SubQ Insulin Therapeutic Inertia Therapy Advisor® Tight Glycemic Control Time in Range Time Savings Transitions of Care Transplant Patients Virtual Care
Glytec Goes Global, With Six New International Patent Allowances
The digital therapeutics pioneer is expanding its intellectual property footprint beyond the U.S., gaining worldwide protections for its proprietary diabetes therapy management solutions.
The rise in diabetes is truly a global phenomenon. The World Health Organization has been vocal about the estimated 422 million people living with diabetes, saying: "the prevalence of diabetes is steadily increasing everywhere" and "diabetes and its complications impact harshly on the finances of individuals and their families, and the economies of nations." Glytec recognizes that optimizing diabetes medications and making insulin a more effective and accessible option stands to benefit not only those living in the U.S, but people around the world. To that end, the company is growing its intellectually property portfolio on an international scale.
Glytec Awarded Patent Allowance for Virtual Insulin Titration in Concert with CGM, Smart Pens and Other Diabetes Technologies
The company's growing intellectual property portfolio attests to its leadership position in diabetes medication optimization in an era of data-driven care.
Glytec, the pioneer of digital therapeutics, has been awarded another patent allowance by the United States Patent and Trademark Office (USPTO). The latest allowance references interactions between the company's software-as-a-medical-device platform for insulin titration and multiple connected diabetes technologies, including continuous glucose monitoring (CGM) systems, smart insulin pens and insulin pumps.
Glytec Receives Another Patent Allowance for Therapy Advisor®
The company is expanding its software-as-a-medical-device platform to support the optimization of ALL diabetes medications.
The United States Patent and Trademark Office has granted Glytec another patent allowance for systems and methods related to a product registered under the brand name, Therapy Advisor®. Currently under development, the new product will extend the company's core competencies beyond insulin optimization to include oral, inhaled and non-insulin injectable diabetes medications.
Glytec Receives Two More Patent Allowances for its Insulin Optimization System
The newest USPTO allowances describe an integrated, connected care model for optimizing insulin therapy in the outpatient setting.
The United States Patent and Trademark Office has awarded Glytec two more patent allowances acknowledging the unique characteristics of its disruptive innovations. The allowances, which comprise a total of 52 claims, describe interactions between Glytec's solution for insulin titration and multiple current and future-state connected diabetes technologies and health information systems, including devices, apps and other form factors for blood glucose measurement, insulin delivery and patient communication.
Two More Patent Allowances for Glytec's Diabetes Software
The latest allowances from the USPTO address systems and methods specific to the dosing of subcutaneous insulin for acute and chronic care.
The United States Patent and Trademark Office (USPTO) has issued two more patent allowances for Glytec's FDA-cleared proprietary software used by healthcare providers to guide the dosing of insulin. The allowances, which comprise a combined total of 52 claims, cite systems and methods specific to subcutaneous basal and bolus insulin. To date, Glytec has amassed an intellectual property portfolio of 18 issued or allowed patents for its eGlycemic Management System® (eGMS®) and has several dozen patents pending.
USPTO Grants Glytec Patent Allowance for Computer-Guided Selection and Dosing of All Diabetes Medications
The new patent allowance addresses personalized optimization of insulin and non-insulin medications alike.
Long recognized as the market leader in enterprise software solutions for insulin management, Glytec is expanding its intellectual property protections with a new patent allowance that addresses the optimization of all diabetes medications, including oral and non-insulin injectable varieties. The patent allowance, issued by the United States Patent and Trademark Office, comprises an intricate series of 24 claims that describe personalized computer-guided selection and dosing of any prescribed diabetes therapy regimen, whether insulin only, non-insulin only or combination.
Glytec Awarded Patent Allowance Supporting Connected Care Model for Insulin Management
The allowed patent encompasses detailed interactions between multiple connected diabetes technologies.
Glytec, the pioneer of personalized digital therapeutics, has been awarded another U.S. patent allowance for systems and methods related to insulin management in the outpatient environment. The new patent allowance comprises 30 individual claims describing a connected care model that harnesses the integration of Glytec's software-as-a-medical-device for insulin titration with multiple current- and future-state connected diabetes technologies and health information systems, including any and all devices, apps and other form factors for blood glucose measurement, insulin delivery and patient communication.
Glytec Receives Five Additional Patent Allowances for its Diabetes Therapy Management Software
Poised to address diabetes on a global scale, the company expands its intellectual property protections in the United States and abroad.
Glytec, the healthcare company behind a market-leading software solution for personalized diabetes therapy management, announces five new patent allowances for its eGlycemic Management System® (eGMS®), increasing the company's portfolio to a total of 11 allowed or issued patents, with more than 50 pending.
Glytec Grows its Patent Portfolio with Another Notice of Allowance for its Precision Diabetes Management Technologies
This latest notice of allowance from the United States Patent and Trademark Office deepens Glytec's intellectual property protections and further validates its leadership stature in the healthcare market.
Glytec today announces another notice of allowance from the United States Patent and Trademark Office (USPTO) for its eGlycemic Management System® (eGMS®), a modularized software-as-a-service solution used by hospitals and health systems for personalized insulin dosing, enterprise glucose surveillance, performance-driven analytics, and more. This latest notice comes on the heels of three others received this past September — adding to U.S. Patent 9,233,204 and U.S. Patent 9,171,343 — bringing the total number of patents held by Glytec to six, with more than 50 U.S. and international patents pending.
Glytec Receives Three Additional Patent Notices of Allowance from USPTO for its Breakthrough Diabetes Technologies
The notices further validate Glytec's position as a leader in advanced technologies and innovations for glycemic management.
The company is aggressively building a patent portfolio that affords protection of its proprietary diabetes technologies. The three new allowances will issue as patents over the next 60 days — adding to U.S. Patent 9,233,204 and U.S. Patent 9,171,343 — bringing the total number of patents held by Glytec to five. The company has more than 30 other U.S. and international patent applications pending.
Glytec Receives Approval from The USPTO on Another Patent
Second allowance covers its unique insulin administration method.
Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application directed toward a method of administering insulin proven to improve patient outcomes compared to antiquated paper protocols. The method entails selecting a precise subcutaneous insulin treatment for each patient based on blood glucose measurements and other patient information, and administering the selected treatment.
Glytec Receives Patent on Innovative Diabetes Management Mobile App
The allowed claims are directed to a system for glycemic control of a diabetic patient that includes a smartphone-based diabetes mobile application, which will provide patients with real-time insulin dosing guidance, leveraging Glytec's proprietary insulin titration technology.
Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering key aspects of the company's core technology for diabetes management.
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes.
©Copyright Glytec, LLC on behalf of Aseko, Inc. | Terms of Use | Legal Disclaimer | Privacy Policy | Contraindications, Warnings and Precautions
The eGlycemic Management System® is a modularized solution for glycemic management across the care continuum that includes Glucommander™. Glucommander™ is a prescription-only software medical device for glycemic management intended to evaluate current as well as cumulative patient blood glucose values coupled with patient information including age, weight and height, and, based on the aggregate of these measurement parameters, whether one or many, recommend an IV dosage of insulin, glucose or saline or a subcutaneous basal and bolus insulin dosing recommendation to adjust and maintain the blood glucose level towards a configurable physician- determined target range. Glucommander™ is indicated for use in adult and pediatric (ages 2-17 years) patients. The measurements and calculations generated are intended to be used by qualified and trained medical personnel in evaluating patient conditions in conjunction with clinical history, symptoms, and other diagnostic measurements, as well as the medical professional's clinical judgement. No medical decision should be based solely on the recommended guidance provided by this software program.
Glucommander™ is only available for use in the United States.
This site is only intended for use in the United States.